Premature ovarian insufficiency should be considered in women younger than 40 years of age with four months or more of menstrual disturbance. It is associated with an increased risk of multimorbidity, such as osteoporosis, cardiovascular disease, infertility and decreased survival. Personalised hormone therapy is the mainstay of treatment and should be initiated promptly and continued until at least the usual age of menopause to minimise the risk of long-term sequelae.
